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Beyond GWASs: Illuminating
the Dark Road from Association to Function
Stacey L. Edwards,1,2,4,* Jonathan Beesley,1,4 Juliet D. French,1,2,4 and Alison M. Dunning3,4
Genome-wide association studies (GWASs) have enabled the discovery of common genetic variation contributing to normal and
pathological traits and clinical drug responses, but recognizing the precise targets of these associations is now the major challenge.
Here, we review recent approaches to the functional follow-up of GWAS loci, including fine mapping of GWAS signal(s), prioritization
of putative functional SNPs by the integration of genetic epidemiological and bioinformatic methods, and in vitro and in vivo experi-
mental verification of predicted molecular mechanisms for identifying the targeted genes. The majority of GWAS-identified variants fall
in noncoding regions of the genome. Therefore, this review focuses on strategies for assessing likely mechanisms affected by noncoding
variants; such mechanisms include transcriptional regulation, noncoding RNA function, and epigenetic regulation. These approaches
have already accelerated progress from genetic studies to biological knowledge and might ultimately guide the development of prog-
nostic, preventive, and therapeutic measures.Introduction
Since the advent of high-density genotyping arrays,
researchers have used genome-wide associations studies
(GWASs) to identify over 1,000 loci associated with a
multitude of physiological traits.1 These studies exploit
the nonrandom coinheritance of genetic variants (linkage
disequilibrium [LD]) to simultaneously assay hundreds of
thousands of markers for an association with any given
trait.2 Given that the SNPs on genotyping chips are
‘‘tags’’ for haplotypes on which the directly functional
variants reside, the next major challenge lies in moving
from associated tag SNPs to finding the strongest candi-
date causal variants and then identifying their target
gene(s). We define a causal variant as one that influences
a molecular or cellular process to affect a human pheno-
type. Contrary to early expectations, few GWAS-identified
variants are predicted to disrupt protein-coding regions,
and approaches to determining their functional conse-
quences are reviewed elsewhere.3 The vast majority of
GWAS tag SNPs lie in intergenic or intronic regions
(approximately 88%1) and therefore are likely to influence
gene regulation (assuming that the same is true for the
correlated candidate causal SNPs). There are now a limited
number of studies that have pursued the function of
GWAS hits, some of which have been defined by fine map-
ping (Table 1). However, the relevance of those studies that
lack comprehensive fine mapping is questionable. Here,
we review recent approaches to post-GWAS fine mapping
and functional evaluation of noncoding variants. Our pro-
posed functional pipeline for the follow-up of GWAS loci
addresses the prioritization of putative functional SNPs
(Figure 1). We describe the integration of genetic data
and statistical analysis, computational approaches, and
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Fine Mapping of Associated Loci
GWASs reveal associations between specific genomic loci
and genetic traits or diseases via a set of marker SNPs
designed to tag all known common variants in the
genome.21 Human history and ancestry have caused com-
plete segments of DNA, termed haplotype blocks, to be
shared within populations.22 A typical haplotype block is
illustrated in Figure 2B, where segments of correlated
SNPs are separated by recombination hot spots (the gaps
between the gray-scale triangular matrices). Patterns of
block structure differ between ethnic groups, and on
average, European-ancestry populations have more highly
correlated SNPs and longer haplotype blocks (Figure 2B,
top panel) than do populations of African or Asian
ancestry (Figure 2B, lower panels).23 It is possible to infer
which type of segment a person carries by typing selected
markers within each haplotype block, obviating the need
to type the majority of variants in the human
genome.2,23 Modern GWAS genotyping chips typically
contain 300,000–5,000,000 SNPs, chosen for their correla-
tion with, and thus ability to tag, as many other human
genetic variants as possible. GWAS tag SNPs are not
selected for having likely functional consequences, and if
any are subsequently recognized, this is simply serendipi-
tous. The conclusion that can be drawn at the end of a
successful GWAS is that one or more genetic variants
within the locus, marked by the associated tag SNP, must
have biological functions that drive the observed associa-
tion. In this review, we use the term ‘‘locus’’ to mean a
haplotype block containing both the GWAS tag SNP and
the directly causal variant (Figure 2).ical Research Institute, Brisbane, Queensland 4029, Australia; 2School of
, Queensland 4072, Australia; 3Department of Oncology, Centre for Cancer
y of Human Genetics. All rights reserved.
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Table 1. Functional Genetic Variants and/or Target Genes Successfully Identified at GWAS Signals
Disease or
Phenotype Locus
Functional SNPs
or Regions Target Gene(s)
Fine
Mappinga Key Methods References
Low-density lipoprotein
cholesterol levels (MIM
605028)
1p13 rs12740374 SORT1 (MIM 602458)  eQTL, reporter assays,
EMSAs, mouse models
Musunuru et al.4
Fetal hemoglobin levels 2p16 rs1427407,
rs7606173
BCL11A (MIM 606557)  3C, ChIP-seq, reporter
assays, transgenic mouse
models, allele-specific
expression, TALENs
Bauer et al.5
Chronic obstructive
pulmonary disease
(MIM 606963)
4q31 rs1542725 HHIP (MIM 606178) þþ 3C, ChIP, reporter assays,
EMSAs
Zhou et al.6
Prostate cancer
(MIM 176807)
5p15 rs12653946 IRX4 (MIM 606199) þþ eQTL, reporter assays, ChIP,
EMSAs
Nguyen et al.7
Breast cancer (MIM
114480), ovarian
cancer (MIM 167000)
5p15 breast and ovarian
cancer risk regions
TERT (MIM 187270) þþ FAIREs, reporter assays,
splicing assays
Bojesen et al.8
Colorectal cancer
(MIM 120435)
8q23 rs16888589 EIF3H (MIM 603912) þþ 3C, reporter assays, EMSAs,
allele-specific expression,
in vivo transgenic assays
Pittman et al.9
Colorectal cancer 8q24 rs6983267 c-MYC (MIM 190080) þ 3C, EMSAs, reporter assays,
allele-specific ChIP,
microarrays, transgenic
mouse models.
Tuupanen et al.,10
Wright et al.11
Prostate, breast, and
colorectal cancer
8q24 prostate, breast,
and colorectal
cancer risk regions
c-MYC  3C, reporter assays, ChIP Ahmadiyeh et al.,12
Sotelo et al.13
CAD (MIM 608320) 9p21 rs10811656 or
rs10757278
CDKN2A (MIM 600160),
CDKN2B (MIM 600431),
MTAP (MIM 156540),
IFNA21 (MIM 147584)
þþ 3C-DSL, ChIP, FISH Harismendy et al.14
CAD 9p21 CAD risk region CDKN2A, CDKN2B  targeted mouse models,
allele-specific expression
Visel et al.15
Breast cancer 10q26 rs7895676,
rs2981578
FGFR2 (MIM 176943)  eQTL, EMSAs, ChIP,
reporter assays
Meyer et al.16
Breast cancer 11q13 rs554219,
rs78540526,
rs75915166
CCND1 (MIM 168461) þþ 3C, reporter assays, EMSAs,
allele-specific ChIP
French et al.17
Renal cancer
(MIM 144700)
11q13 renal cancer risk
region
CCND1  ChIP, FAIREs, 3C,
three-dimensional FISH,
allele-specific expression
Schodel et al.18
Asthma (MIM 600807)
and autoimmune
disease (MIM 109100)
17q12
17-q21
rs12936231,
rs80667378
ZPBP2 (MIM 608499),
GSDMB (MIM 611221),
ORMDL3 (MIM 610075)
þþ FAIREs, allele-specific ChIP,
EMSAs, reporter assays
Verlaan et al.19
Prostate cancer 17q24 rs8072254,
rs1859961
SOX9 (MIM 608160)  3C, reporter assays,
ChIP-seq, allele-specific ChIP
Zhang et al.20
Abbreviations are as follows: 3C, chromatin conformation capture; 3C-DSL, 3C with DNA selection and ligation; CAD, coronary artery disease; ChIP, chromatin
immunoprecipitation; ChIP-seq, ChIP sequencing; eQTL, expression quantitative-trait loci; EMSA, electrophoretic mobility shift assay; FAIRE, formaldehyde-
assisted isolation of regulatory element; FISH, fluorescence in situ hybridization; and TALEN, transcription-activator-like effector nuclease.
aSymbols are as follow: , no fine mapping; þ, fine mapping using imputation from the GWAS tag SNPs; and þþ, dense genotyping and imputation or
resequencing of LD block.Successful fine-scale mapping, intended to identify the
truly functional variants underlying observed GWAS sig-
nals, requires as a startingpoint a complete catalogof all var-
iants in the associated locus. The working principle is that
the functional variants being sought must be contained in
the initial list. For a number of years after the publication
of successful GWASs, generating such a catalog was the
rate-limiting step. During this period, targeted sequencing780 The American Journal of Human Genetics 93, 779–797, Novembof the locus in DNA from sufficient subjects was needed
for ensuring the identification of all variants that could
conceivably explain the association.24 Most common vari-
ants are found from the sequencing of relatively few DNA
samples, but progressively more samples must be
sequenced for identifying increasingly rarer variants. This
process has been technically demanding, time consuming,
and very costly; consequently, very few loci have beener 7, 2013
Figure 1. Workflow for Functionally Analyzing and Interpreting GWAS Lociexamined by this route. The public availability of the 1000
Genomes Project data25 has provided the necessary break-
through to grant all researchers access to sufficiently
comprehensive sequence data fromwhich to compile their
catalogs. This data set currently comprises 1,092 subjects,
drawn from eachmajor human ancestry, and has sufficient
sequencing depth for all discoverable polymorphic variants
(minor allele frequency > 1%) to be found.25
Once a comprehensive SNP catalog becomes available, the
next requirement is to genotype these SNPs in DNA from
studies in which the phenotype of interest has been accu-
rately measured. The key to success is statistical power,
most often developed by collaborating international
consortia with a shared interest (e.g., Wellcome Trust Case
Control Consortium,26 Genetic Investigation of Anthropo-
metric Traits,16 and Breast Cancer Association Consortium
[BCAC]27). These consortia have also generated their
own genotyping chips for fine-scale-mapping loci they
have discovered (e.g., Immunochip,28 Metabochip,29 andThe AmericaniCOGs).30 To date, the majority of GWASs and mapping
studies have been performed in European-ancestry popula-
tions, which tend to have longer haplotype blocks contain-
ing many highly correlated SNPs.23 This pattern provides a
GWAS advantage of requiring fewer tag SNPs for genome-
wide coverage but a subsequent fine-mapping disadvantage
due to associated loci containing many correlated SNPs,
mostofwhicharenotdirectly causal. Typically, study sample
sizes ranging from 10,000 to 100,000 have been required for
teasing apart the small differences in risk associated with
different SNPs.31 The aim is to separate variants displaying
the greatest associations (the best candidate causal variants)
fromthosewith strongbut significantly lesser associations so
that themajorityofvariants inagiven locus canbe rationally
excluded from further consideration. The ability to discrim-
inate between gradations in degree of association is a func-
tion of study power, which in turn is affected by the magni-
tude of the effect of the causal SNP and the sample size.31 In
addition to available sample size, other limiting factors areJournal of Human Genetics 93, 779–797, November 7, 2013 781
Figure 2. Integrated Genetic and Genomic Data at the 11q13 Breast Cancer Susceptibility Locus
(A) Manhattan plot displaying the strength of genetic association (log10 p) versus chromosomal position (Mb). Each dot represents a
genotyped or imputed SNP. Dot colors signify the degree of pairwise correlation (r2) with the top SNP, as presented in the color key.White
dots depict SNPs for which r2 values are unknown. The gray shaded stripe represents the iCHAV, encompassing a physical area bound by
(legend continued on next page)
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the cost of genotyping anddifficulties indeveloping success-
ful assays for every genetic variant under consideration,
because no single genotyping platform can analyze all
possible variant types. Imputation techniques (such as
IMPUTE2), which use known correlations between SNPs
(e.g., from the 1000 Genomes Project data) to estimate the
probable genotype of any SNP in a subject,31 have overcome
thishurdle. This approachaims tofill inall themissinggeno-
type data (with a known degree of accuracy) in any data set
and can be used when the relevant SNPs are not included
on the platform or because the genotyping failed. After
imputation, a complete data set containing all genotyped
or imputed SNPs within a locus should be compiled for all
subjects.
Loci vary enormously both in physical length and in the
number of common genetic variants that they contain. It is
not unusual for a locus to be >100 kb long and to contain
>1,000 variants, of which hundreds might display signifi-
cant associations with the phenotype of interest. Each
causal variant lies within an independent set of correlated,
highly trait-associated variants, which we have termed an
‘‘iCHAV.’’ An iCHAV resulting from an association study is
broadly analogous to the ‘‘linkage peak’’ identified via a
familial linkage study. For example, Figure 2B (green bar)
illustrates a tight ~30 kb haplotype block in all ethnicities
at the right-hand side of the diagram and a less defined
0.3 Mb block comprising several smaller blocks (Figure 2B,
purple bar) containing an iCHAV (Figure 2C, gray area) in
Europeans. Exclusion of noncasual variants begins with
the identification of the number of iCHAVs within a given
locus, typically by forward conditional logistic regression
analysis. Haplotype analysis can also be useful for exam-
ining the interrelationship of multiple putatively causal
SNPs.32 Such analysis proved particularly revealing in the
fine-scale mapping of the 11q13 breast cancer locus
(Table 1).17 Indeed, fine mapping revealed several more
strongly associated variants than the original GWAS tag
SNP, rs614367 (Figure 2A).17,33 If a single iCHAV is identi-
fied, the next stage is straightforward: the SNP showing
the strongest phenotypic association (the one with the
greatest effect size andmost significant association p value)
is assumed to be the best candidate for causation, and rela-
tive to this one, other variants within the same iCHAV
can be excluded from further consideration by means of a
likelihood ratio test.31 As a rule of thumb, just as in aBonfer-SNPs that are statistically indistinguishable by stepwise conditional
dotted line represents the threshold for genome-wide significance (p
(B) Linkage disequilibrium plots depicting pairwise correlation betw
(CEU), African (YRI), and Asian (CHB) populations. The plots are in gr
The pink and green bars denote haplotype blocks described in the te
(C) Inset from panel (A). The UCSC Genome Browser was used for v
function. The pink stripe indicates the genomic region corresponding
are shown as red marks. Regions of open chromatin, indicative of put
(DHSs) and are marked. ChIP-seq data for histone marks associated w
shown. The ENCODE ChromHMM track represents integrated anal
human mammary epithelial cells (HMECs). Color coding is as follo
promoter; blue, insulator; gray, repressed. RNA Pol II ChIA-PET data
indicate more frequent interactions.
The Americanroni correction, it is considered safe to exclude all variants
with likelihood ratios >100 times worse than the strongest
SNP in the iCHAV.31 This stage removes from further
consideration all SNPs simply associated with a phenotype
because they are carried on the samehaplotype as the stron-
gest candidates because of shared ancestral history. Under
ideal circumstances, i.e., with a sample size large enough
for adequate power, it might be possible to exclude all but
the most strongly associated variant. In practice, because
of the high degree of shared ancestry in European popula-
tions, there can be many very highly correlated variants in
any given iCHAV, leading to difficulty identifying single pu-
tative causal variants from genetic epidemiological studies
alone. More often, at the end of this stage there remain
10–50 highly correlated, strong candidates, all with good
likelihood ratios relative to the best hit,8,17,24,34 in one or
more iCHAVs underlying the original GWAS association.
Under appropriate conditions, it can be possible to use
studies from different ethnicities to further reduce the
remaining number of candidates.35 The necessary condi-
tions are that the same association must be observable in
collected study samples from more than one ethnicity
and that the patterns of SNP correlation must differ
between the different ethnic groups. Given adequate
sample sizes, it should thus be possible to exclude more
candidates by using similar studies from different ethnic
groups, but in practice the haplotype structure at the locus
of interest is not always favorable.36
We began this type of fine-scale mapping of breast cancer
lociwithin theBCACwith theworkinghypothesis that a sin-
gle functional variant, in a single iCHAV,would explain each
GWAS hit. However, among the nine breast cancer loci we
examined in sufficient detail, and in reports from others,
there is now strong evidence of the existence ofmultiple, in-
dependent functional variants at many GWAS-discovered
loci.8,17,28,37–40 In some loci, these are carried on separate
haplotype backgrounds (and separate iCHAVs), indicating
that they result from separate mutational events. In other
loci, multiple, apparently functional variants occur together
on the samehaplotype background (within a single iCHAV),
generating additive effects on cancer risk.17,36 The discovery
of multiple causal variants at loci originally thought to
contain only one will explain more ‘‘missing heritability’’41
than previously calculated from the GWAS results alone.39
Moreover, early findings indicate that independent variantsanalysis and including the GWAS lead SNP rs614367. The purple
¼ 5 3 108).
een SNPs genotyped in the 1000 Genomes Project for European
ayscale, for whichwhite and black signify r2¼ 0 and 1, respectively.
xt in relation to transethnic fine mapping.
isualizing ENCODE data tracks, which are indicative of regulatory
to the iCHAVat 11q13, and the locations of the fine-mapped SNPs
ative regulatory signals, are detected as DNaseI hypersensitive sites
ith regulatory regions and specific TFs relevant to breast cancer are
ysis of chromatin states based upon histone ChIP-seq data from
ws: green, weak transcription; yellow and orange, enhancer; red,
from MCF7 cells are represented as a grayscale bar; darker regions
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Table 2. Computational Tools and Resources for the Analysis of GWAS Loci
Feature Description Significance Experimental Approach
Bioinformatic Tools and
Online Resourcesa
Open
chromatin
nucleosome-depleted chromatin sequences harboring
regulatory signals
DNase-seq, FAIRE sequencing ENCODE, NIH Roadmap
Epigenomics Project,
RegulomeDB, HaploReg,
FunciSNP
TF-binding
prediction
short DNA consensus recognition
sequence characteristic of a
particular DNA-binding protein
computationally predicted
TF recognition site
position weight matrices TRANSFAC, JASPAR, MAPPER2
DNA-protein
interaction
short DNA sequence associated
with a DNA-binding protein
after precipitation with a specific
antibody
physical protein-nucleic-acid
binding (note: no direct
evidence of activity)
ChIP-seq, DNase footprinting ENCODE, NRCistrome,
RegulomeDB, HaploReg
DNA
methylation
methylation of cytosine residues
in CpG dinucleotides
repression of gene expression methylation array, bisulphite
sequencing, MeDIP-seq, MRE-seq
ENCODE, NIH Roadmap
Epigenomics Project,
MethDB, EpiGraph
RNA
expression
detection and measurement of
transcribed RNA
coding RNA, noncoding RNA,
alternative splicing
RNA-seq, RNA-PET, CAGE ENCODE, Gene Expression
Omnibus, Galaxy
Histone
modifications
specific posttranslational
modifications of particular
histone protein residues are
associated with various
regulatory activities
H3K4me1: promoters and
enhancers
H3K4me2: promoters and
enhancers
H3K4me3: promoters
H3K79me2: transcription
transition
H3K27ac: active regulatory
region
H3K9ac: promoters
H3K9me1: active chromatin
H3K9me3: repressed
chromatin
ChIP-seq ENCODE, NIH Roadmap
Epigenomics Project,
NRCistrome, RegulomeDB,
HaploReg, ChromHMM,
GWAS3D, Segway, ChroMoS
Chromatin
interactions
long-range physical interactions
between distal genomic regions
contact between regulatory
motifs, such as tissue-specific
enhancers and promoters
3C, 4C, 5C, 6C, Hi-C, ChIA-PET GWAS3D, Hi-C Project,
ChIA-PET Browser
Abbreviations are as follows: 3C, chromosome conformation capture; 4C, circular 3C; 5C, carbon-copy 3C; 6C, combined 3C-ChIP-cloning; CAGE, cap analysis
gene expression; DNase-seq, DNaseI hypersensitive site sequencing; MeDIP-seq, methylated DNA immunoprecipitation sequencing; MRE-seq, methylation-
sensitive restriction enzyme sequencing; and RNA-PET, RNA paired-end-tag sequencing.
aNonexhaustive list of examples.within a given locus can disrupt the same target gene by
differing mechanisms and are consequently associated
with differing magnitudes of risk.8,17 Clearly, these data are
contingent on comprehensive fine mapping for ensuring
that the genuinely causal variant(s) is captured prior to func-
tional assessment.With the list of SNPs that cannot be elim-
inated from consideration by statistical fine-scale mapping
studies as a starting point, the next challenge is to elucidate
the mechanism by which each candidate variant might
influence the expression of its target gene(s). Functional
evaluation of noncoding, regulatory variants requires
the stepwise application of an array of computational
approaches, including database searches and application of
in silico tools, as well as a subsequent range of molecular
experimental techniques (Figure 1).
Using Publically Available Data to Guide Functional
Analyses
Many noncoding SNPs reside within regulatory sequences
and influence gene expression through transcriptional,
posttranscriptional, and posttranslational mechanisms.
Transcription is a complex process dependent on a coordi-784 The American Journal of Human Genetics 93, 779–797, Novembnated interplay between protein-DNA and protein-protein
interactions (reviewed in Kadonaga42). RNA polymerase II
(RNA Pol II) assembles at gene promoters with the basal
transcription machinery, and numerous transcription fac-
tors (TFs) and accessory molecules are recruited to alter
the function of RNA Pol II by associating with regulatory
sequences. The accessibility of these factors is dependent
on chromatin structural changes mediated by posttransla-
tional histone modifications, such as methylation and
acetylation.43 Importantly, regulatory signals can act over
long genomic distances and are brought into contact
with target promoters via three-dimensional DNA folding.
Computational approaches to assigning potential regula-
tory function to noncoding SNPs have been greatly
enhanced by the recent emergence of several large-scale
genome-wide data sets. Data made publically available by
projects such as ENCODE, Nuclear Receptor Cistrome
(NRCistrome), and the National Institutes of Health
(NIH) Roadmap Epigenomics Project can be routinely
mined with a range of tools for the annotation of noncod-
ing variants with a potential impact on regulatory mecha-
nisms (Table 2). Regulatory function can be predicted oner 7, 2013
the basis of particular genomic features, such as histone
modifications, open chromatin, and TF binding, which
are measured with targeted biochemical assays and high-
throughput sequencing technologies (Figure 2C).Mapping
these data to a region of interest can then facilitate the
design of additional functional analyses.
A range of computational tools, including RegulomeDB,
HaploReg, and FunciSNP, are available for specifically
querying these data sets (Table 2). With these, the genera-
tion of hypotheses to test candidate-SNP effects can be
prioritized for experimental assessment. These programs
test the potential impact of sequence variation on several
genomic features, including gene and isoform annota-
tions, expression quantitative-trait loci (eQTL), chromatin
immunoprecipitation sequencing (ChIP-seq), DNaseI
hypersensitive site (DHS) sequencing, chromatin interac-
tions, evolutionary sequence conservation, and TF-bind-
ing motifs. It is important to incorporate fine-mapping
genetic data (i.e., the best candidate SNPs) into these ana-
lyses, and this can be easily achieved with GWAS3D, which
is capable of analyzing an entire GWAS output. Because
these tools are freely available online, the combined
outputs should be routinely used for triaging variants for
further characterization (Table 2). It should be noted that
many tools rely on ENCODE data, which are not exhaus-
tive (i.e., limited TFs and cell types have been assayed),
so there is also a high probability of false negatives, for
example, where missing data might lead to the absence
of valid results. Conversely, these programs do not take
into account tissue specificity, which could lead to false
positives, such as where SNPs might influence signals in
irrelevant cell types. Overall, with the consideration of
the specific biological question, computational approaches
currently represent a useful starting point to guide the
design of functional assays.
Potentially interesting results from such tools can be
further interrogated via manual investigation of specific
loci in the UCSC Genome Browser, which is able to display
customizable ENCODE and NIH Roadmap Epigenomics
Project data. Experimental matrices that display all avail-
able data are a starting point for loading various ‘‘tracks’’
into the browser. Users are also able to upload data,
including SNP positions of interest or experimental data
retrieved from repositories such as the NCBI Gene Expres-
sion Omnibus and NRCistrome. Other notable features
include ‘‘sessions,’’ or configurations of track sets that
can be shared between users, and the ‘‘table browser’’
feature, which provides a means by which the database
can be queried for automated analyses.
Analysis of LD patterns is facilitated through the use of
several key resources, including the HapMap and 1000
Genomes projects. Downloaded genotype data covering
specific loci can be visualized and manipulated with
HaploView44 for investigating haplotype structure and fre-
quency (Figure 2B). LD patterns can be compared between
ethnicities, enabling the determination of variant segrega-
tion in different populations. Several online resources,The Americanincluding the SNP Annotation and Proxy Search tools at
the Broad Institute and LocusZoom, enable plotting of
association data with LD information. Figure 2A demon-
strates how pairwise correlation r2 coefficients can be
related to a lead SNP via color coding.
Several elegant examples utilizing these computational
approaches have recently been published. Maurano et al.
showed that GWAS signals were overrepresented in regula-
tory regions by assessing the frequency of variant
occurrence in DHSs generated by the ENCODE and NIH
Roadmap Epigenomics consortia.45 Furthermore, assess-
ment of putative functional variants at the 17q24.3 pros-
tate cancer risk locus with the use of ENCODE and NIH
Roadmap Epigenomics Project data facilitated the identifi-
cation of a prostate-specific enhancer.20 We used mam-
mary-cell-specific ChIP-seq signals from ENCODE and
NRCistrome to assess potential regulatory functions at
the 11q13 breast cancer risk locus, where we ultimately
showed that CCND1 is a target of that association
(Figure 2C).17 These resources are extremely useful pro-
vided that the cell and tissue typesmost relevant to the dis-
ease state under study have been assayed. For example,
limited data are currently publically available for ovarian
tissues, precluding the approaches outlined above in
preliminary investigations for the correlation of ovarian
cancer risk alleles in regulatory signals. Furthermore, there
are limits to the availability of tissues at each develop-
mental stage or under exposures to different environ-
mental conditions.
Pathway-based analyses are another strategy being used
for prioritizing genes from GWAS-identified regions (re-
viewed in Wang et al.46). These approaches typically
examine whether a group of genes in the same biological
pathway are jointly associated with a GWAS trait. The
advantage of using these approaches is that important
biological pathways underlying the GWAS trait can be
uncovered. However, caution should be taken because
these types of analyses are based on the often incorrect
assumption that SNPs can be assigned to genes on the basis
of proximity or the LD block in which they reside. In addi-
tion, prior biological knowledge about the genes and path-
ways is also required, thus undermining the agnostic
nature of the GWAS approach.
eQTL
Levels of gene expression are highly heritable,47,48 and spe-
cific genomic regions containing variants that influence
gene expression are known as eQTL. Multiple studies
have provided strong evidence that GWAS signals are
enriched with eQTL in a tissue-specific manner,49,50 high-
lighting their utility in understanding the mechanisms
underlying GWAS hits. Many resources, including online
databases such as GeneVar, are now available for eQTL
analyses. Importantly, eQTL annotation is carried out in
an unbiased fashion; hence, associations between alleles
and target genes require no prior knowledge of functional
mechanisms. Although GWAS variants can be associatedJournal of Human Genetics 93, 779–797, November 7, 2013 785
with expression (ideally in a relevant tissue type), addi-
tional functional assays are required for confirming the
mechanistic relevance to the disease or trait. A recent
approach interrogated cancer-derived samples by using
RNA sequencing (RNA-seq) and correlated allelic imbal-
ance (AI) to breast cancer risk genotypes.51 Importantly,
the analysis adjusted for copy number and methylation,
significant confounders when gene expression is exam-
ined in tumor material.
Given that somatic alterations present in tumor cells
can greatly affect expression, subtle genotype-associated
influences can be undetectable.52 It is therefore ideal to
measure eQTL effects in normal cells, representative of
the cell of origin for the disease under study. This is partic-
ularly important because it is estimated that 50%–90% of
eQTL are tissue dependent,50,53 and trait-associated vari-
ants tend to exert more tissue-specific effects.54,55 Not
surprisingly, Fu et al. also showed that SNPs that fall in
regulatory regions of the genome are also more likely to
confer tissue specificity.54 To date, most eQTL data sets
are derived from only a limited number of source cell
types, including monocytes,56 lymphoblastoid cells,53
and brain cells.57 In an effort to address this issue, a large
NIH-funded project known as Genotype Tissue Expression
has been initiated with the aim of characterizing eQTL in
more than 60 different normal tissues from 900 indi-
viduals.
Several factors must be considered when eQTL data are
used. The majority of identified eQTL are cis-acting, arbi-
trarily defined as regulation of genes within 1 Mb, given
that their effect sizes are usually relatively large and can
be detected with smaller sample sizes.58 However, genetic
variants can also affect the expression of genes that reside
further away or are on different chromosomes (trans-
eQTL).59 Notably, Fehrmann et al. identified independent
trans-associated SNPs affecting similar genes, suggesting
that independent GWAS associations might influence
similar biological pathways.60 Haplotype might also influ-
ence eQTL effects:61 because LD patterns are population
specific, association between variants that tag a haplotype
could lead to the ambiguous identification of the true
casual SNP. Furthermore, the target genes of eQTL associa-
tions could be coding or noncoding RNAs,62 although
small RNA expression is not measurable by certain plat-
forms. Recent RNA-seq experiments have revealed that
genotype can also influence alternative isoform produc-
tion,63 and variation in mRNA stability is also known to
be under the control of correlated alleles.64 As with GWASs
for any complex trait, the analysis of eQTL across diverse
populations will enable more accurate mapping of regula-
tory variants.48,53,65 Variation in levels of specific protein
isoforms have also recently been shown to be heritable.66
It should be noted that identifying an eQTL provides
only indirect evidence of a link between genotype and
gene transcription. Elucidating the involved mechanisms
will then rely on a range of molecular approaches, which
we describe below.786 The American Journal of Human Genetics 93, 779–797, NovembRegulatory Variation at GWAS Loci
The recent fine mapping and functional characterization
of GWAS variants have indicated that cis-regulation is a
common mechanism underlying these associations.4,8,17
The most frequent elements affected are transcriptional
enhancers and silencers. These elements are typically
locatedmore than 1 kb from their target genes and regulate
transcription through long-range interactions, mediated
by the formation of chromatin loops.35 The ability to iden-
tify the target gene(s) of cis-regulatory variants is key to
understanding the mechanism by which GWAS variants
act. The identification of eQTL can be used for predicting
the target genes; however, this strategy usually only pro-
vides indirect evidence of an association, and experimental
approaches are necessary for confirming its mechanistic
relevance.
A more direct approach is to use chromatin conforma-
tion capture (3C), a technique that converts chromatin
interactions into specific ligation products, which are
then quantified individually by real-time PCR.67 3C has
already been used for successfully identifying the target
gene of several regulatory variants identified through
GWASs. For example, we fine mapped the 11q13 breast
cancer risk locus and showed that the strongest signal
mapped to a transcriptional enhancer that distally regu-
lates the CCND1 promoter, located 125 kb away (Figure 2).
17 SNPs associated with chronic obstructive pulmonary dis-
ease at 4q31 also lie within a transcriptional enhancer and
physically interact with the HHIP promoter, located 85 kb
away.6 In both of these cases, the target promoter of the
regulatory elements is the closest gene. However, recent
analysis by the ENCODE Consortium shows that only
27% of the distal regulatory elements have an interaction
with the nearest promoter,68 suggesting that the nearest
gene is often not the target of a given GWAS association.
For example, the likely causal variant for a GWAS associa-
tion at 1p13 with low-density lipoprotein cholesterol is
rs12740374, which lies in a transcriptional enhancer and
alters the activity by creating a C/EBP TF-binding site.4
On the basis of the strong correlation with expression in
the liver, the likely target gene of this cis-regulatory variant
is the fourth-closest gene, SORT1. ENCODE data also sug-
gest that the average number of local target genes of a distal
regulatory element is 2.5, indicating that genetic variants
located in cis-regulatory elements might influence transac-
tivation of multiple promoters and therefore directly affect
the expression of more than one gene.68 Indeed, our
unpublished data indicate that the variants responsible
for the association at the 11q13 breast cancer risk region
affect at least one more gene in addition to CCND1.
3C has two principle limitations. First, it is not possible
to distinguish relevant nearby chromatin interactions
(within ~20 kb) above background interactions caused by
random collisions. Second, 3C can only detect specific
interactions between prespecified regions because it relies
on PCR primers designed across interacting regions. To
overcome these limitations, researchers have developeder 7, 2013
several variations of the 3C method so as to provide unbi-
ased approaches to identifying the target gene of regula-
tory elements. Circular 3C (also called 4C) allows the entire
genome to be screened for sequences that contact a specific
DNA or ‘‘bait’’ region by means of inverse PCR with bait
primers from a circular intermediate of 3C. Limitations of
4C include (1) the inability to identify interactions around
the ‘‘bait’’ region, (2) the lack of resolution (~100 kb to 1
Mb), (3) that the choice of enzymes used might preclude
the identification of some interactions, and (4) that trans-
interactions (interchromosomal) and distal cis-interactions
(>500 kb from the bait) need to be further validated by
independent methods such as fluorescence in situ hybrid-
ization. Despite these limitations, using the 4C method,
Patel et al. showed that aberrant TAL1 (MIM 187040)
expression in human T cell acute lymphoblastic leukemia
(T-ALL [MIM 613065]) is mediated by a T-ALL-specific
interchromosomal interaction between the TAL1 pro-
moter on chromosome 1 and a regulatory element called
TIL16 (TAL-1 interacting locus on chromosome 16) on
chromosome 16.69 These observations imply that the
target gene(s) of any given GWAS hit could also be located
on a different chromosome. To date, however, 4C
approaches have not been applied to GWAS loci, and until
such time, it is difficult to assess the contribution of inter-
chromosomal interactions to common disease.
Other genome-wide variants of the 3C method provide
unbiased methods for identifying long-range chromatin
interactions. Carbon-copy 3C (also known as 5C) detects
all chromatin interactions across large genomic regions
by using multiplex PCR in combination with high-
throughput sequencing or microarrays.70 Using a similar
technique, coined 3C with DNA selection and ligation,
Harisemendy et al. showed that cis-regulatory variants
associated with coronary artery disease (CAD) interact
with four genes, including IFNA21, located more than
900 kb away. The CAD risk alleles disrupted a binding
site for STAT1, a well-known effector of interferon sig-
naling, and treatment of cells with interferon-g increased
the frequency of the interaction between the enhancers
and IFNA21.14
Chromatin interaction analysis by paired-end-tag
sequencing (ChIA-PET), another variation of 3C, detects
chromatin interactions bound by a specific protein.71
Fullwood et al. originally developed ChIA-PET to map
chromatin interactions bound by estrogen receptor (ER)
from breast cancer cells treated with estrogen. By mining
these data, we identified chromatin interactions between
the CCND1 promoter and a transcriptional enhancer
harboring genetic variants associated with ER-positive
breast cancer (Figure 2C).17 Additional ChIA-PET data
sets for CTCF (CCCTC-binding factor), RNA Pol II, and
H3K4Me2 (a chromatin modification associated with
enhancers) are now available for several different cell
lines.72–74 An obvious limitation of ChIA-PET is the fact
that any given TF is only expected to be involved in a
subset of chromatin interactions, so ChIA-PET data setsThe Americanwill thus not include all promoter-enhancer interactions.
However, it might be possible to identify the majority of
promoter-enhancer interactions by using antibodies
against the general TFs (such as RNA Pol II) or chromatin
modifications (such as H3K4Me1 and H3K4Me2) together
with deeper sequence read depth.72,73 Given that cis-
regulatory elements are highly tissue specific, future chro-
matin-interaction profiles generated in multiple cell lines
will be an invaluable resource for post-GWAS studies.
Once the target gene(s) of a regulatory element has been
established, the impact of SNP(s) on the transactivation of
a specific promoter can be tested via standard reporter
assays. In these assays, regulatory elements are cloned
into a promoter-driven reporter construct and transiently
transfected into relevant cell lines. The effect of individual
SNPs, or preferably the risk haplotype, can then be
compared to the common allele or haplotype constructs.
Importantly, the effect of the SNP(s) might vary depending
on the promoter used to drive reporter expression. Viral
promoters are commonly used for assessing enhancer
activity; however, it should be noted that promoter-
specific effects can be overlooked. The choice of cell type
is also important because cis-regulatory elements are high-
ly tissue- and cell-type specific. For example, a recent study
revealed very different activities of eleven enhancers across
four mammary epithelial cell lines, emphasizing the
importance of conducting these assays in various cellular
contexts.75 Reporter assays can also be used for mapping
DNA regions harboring regulatory activity. This is particu-
larly useful when limited information regarding the regula-
tory potential is available. For example, functional
enhancer mapping of a 40 kb region at the 8q21 ovarian
cancer risk locus identified two regulatory regions that
harbor risk-associated SNPs.76
DNA variants can also affect chromatin looping, a mech-
anism distinct from transactivation.77 Allele-specific chro-
matin interactions can be detected by direct sequencing of
3C products.11,17 However, the SNP needs to be relatively
close to a 3C restriction site for this to be feasible. The
assessment of allele-specific protein binding is also impor-
tant given that the majority of regulatory functions (such
as chromatin looping and transactivation) are mediated
through TFs and other proteins. Computational prediction
of TF binding is the most widely used method for identi-
fying candidate TFs. These predictions are based onmodels
called position weightmatrices, which quantitatively score
the likelihood of observing a particular nucleotide at a
specific position of the known or candidate TF-binding
site. Many web-based programs such as MAPPER2 provide
easily searchable platforms that combine motifs docu-
mented in databases such as JASPAR and TRANSFAC
(Table 2). Recent mapping of histone modifications by
means of ChIP-chip (ChIP followed by microarray hybrid-
ization) or ChIP-seq technologies provides a complemen-
tary approach to predicting TF-binding sites.78 However,
ChIP assays are limited in that each experiment profiles
just one TF, and it is difficult to determine the preciseJournal of Human Genetics 93, 779–797, November 7, 2013 787
binding site for a factor because of the low resolution of the
assay. Protein binding can be assessed with in vitro assays
such as electrophoretic mobility shift assays (EMSAs), for
which knowledge of the bound proteins is not required.
Antibodies against TFs of interest are then used in
supershift EMSA experiments for testing which proteins
mediate allele-specific binding. High-throughput TF-
binding methods, such as proteome-wide analysis of
SNPs (PWAS), that utilize quantitative mass spectroscopy
can also be used for screening SNPs for differential TF
binding.79 An advantage of this technique is that multiple
SNPs can be assayed and the TF can be identified in one
experiment. By applying PWAS to twelve fine-mapped
SNPs associated with type 1 diabetes (MIM 222100), Butter
et al. identified at the IL2RA (MIM 147730) locus four SNPs
that displayed preferential binding of common TFs.79
Allele-specific protein binding should also be verified by
ChIP experiments because the in vitro nature of EMSAs
and PWAS can generate false-positive results. The effect
of these proteins on transactivation in the presence and
absence of a SNP can then be tested by cotransfection in
reporter assays.
Noncoding RNAs at GWAS Loci
Many post-GWAS studies have focused on cis-regulatory
variation to explain disease associations. However, it is
becoming increasingly clear that risk variants can also
affect the expression or function of noncoding RNAs
(ncRNAs). These regulatory ncRNAs can be divided into
two broad categories according to size: (1) small RNAs
(<200 bp), such as microRNAs (miRNAs), small nucleolar
RNAs (snoRNAs), and piwi-interacting RNAs (piRNAs);
and (2) long noncoding RNAs (lncRNAs; >200 bp), which
are often spliced transcripts transcribed from both DNA
strands.
miRNAs typically regulate gene expression through
binding to 30 UTRs of target mRNAs to direct their post-
transcriptional repression.80 Recent studies have indicated
that sequence variation in target genes can modulate
miRNA activity. For example, Kulkarni et al. demonstrated
that variation within the 30 UTR of HLA-C (MIM 142840)
affects binding by miR-148 and thus results in differential
cell-surface expression levels of HLA-C allotypes.81 Their
findings provided themechanism for a linked HIV-control-
associated SNP located 35 kb upstream ofHLA-C.82 Predict-
ing potential target genes is the major challenge in
exploring miRNA function, given that a single miRNA
can potentially regulate hundreds of different genes. A
variety of computational tools, including TargetScan and
PicTar, are available for miRNA target prediction, and
several databases have also been developed for linking
polymorphisms in predicted miRNA-binding sites with
complex traits. It should be noted that most of these pro-
grams rely on target-prediction algorithms that only assess
the possibility of interaction, and so all predictions need to
be experimentally validated. With the increasing avail-
ability of data from deep-sequencing and crosslinking-788 The American Journal of Human Genetics 93, 779–797, Novembimmunoprecipitation projects,83 a few groups have now
tried to characterize the relationship among genetic varia-
tion, miRNA, and gene expression on amore genome-wide
scale.84,85 Collectively, the results indicate that genetic
variants within the 30 UTRs of susceptibility genes at
miR-binding sites are associated with disease risk and
should be routinely considered in post-GWAS functional
studies.
Although it is clear that lncRNAs are important for regu-
lating gene expression, their role in influencing disease
susceptibility is only now being realized. Several studies
have shown that lncRNAs are transcribed from genomic re-
gions associated with disease risk.ANRIL (MIM 613149), an
antisense lncRNA expressed from the CDKN2B-CDKN2A
locus, spans 126 kb and appears to be a hot spot of
GWAS hits.86 SNPs within this locus are associated with
multiple genetic diseases, including diabetes, coronary
heart disease, glaucoma (MIM 231300), and multiple
cancers. Although it cannot be ruled out that these SNPs
affect other genes at this locus, the disease-associated vari-
ants are more strongly correlated with ANRIL expression in
peripheral blood than with that of two nearby genes,
CDKN2A and CDKN2B.86 Fine mapping of this region
and functional studies in the relevant cell types will be
required for confirming that ANRIL is the main target of
these genetic associations. Another example is the
thyroid-specific lncRNA PTCSC3 (MIM 614821), which is
transcribed from a locus associated with papillary thyroid
carcinoma (PTC [MIM 188550]). SNP rs944289, which is
significantly associated with PTC, lies in the promoter of
PTCSC3 and is associated with increased expression in
normal thyroid tissue.87 Conversely, rs944289 is associated
with decreased PTCSC3 expression in PTC, suggesting that
the effects of this SNP differ in normal andmalignant cells.
Lastly, genetic variants within a gene desert at 8q24 are
associated with multiple cancers, including breast, pros-
tate, and colorectal cancer.37 The most likely target gene
at this locus is c-MYC (although it has been difficult to
demonstrate this link), but it is worth noting that several
lncRNAs, as well as a miRNA cluster (miR-1204-1208),
are produced from this locus. These ncRNAs could
either work alone or in concert with c-MYC to explain
the association.
As more RNA sequencing data in relevant tissues become
available, it is likely that other lncRNAs will be identified at
risk loci identified by GWASs. In addition, new tech-
nologies for identifying rare transcripts, a common feature
of lncRNAs, will be important given that it is now clear that
exhaustive sequencing of the human transcriptome has
not been achieved with standard RNA-seq. For example,
Mercer et al. developed a technique termed RNA-
CaptureSeq, which achieves deeper sequencing of tran-
scripts derived from targeted regions.88 As in targeted
genomic sequencing, cDNAs are hybridized onto tiling
arrays prior to sequencing, thus enriching for a specific
fraction of the transcriptome and allowing deeper
sequencing with the same amount of sequence reads.er 7, 2013
With this technology, targeted capture of ~50 human
genes identified 200 new protein isoforms and 163
lncRNAs at or near protein-coding genes, providing
evidence that the human transcriptome is more complex
than previously thought. Application of this technology
in relevant tissues could uncover entirely newmechanisms
for the genetic associations identified by GWASs.
A battery of techniques will then be required for eluci-
dating how individual SNPs affect lncRNA function.
Similar to protein-coding genes, some SNPs are likely to
fall in regulatory elements of lncRNAs, just as rs944289
falls within the promoter of the PTCSC3 lncRNA.87 These
SNPs could be analyzed with methods similar to those
described above. Other SNPs could fall within the lncRNA
transcript itself and therefore influence lncRNA function
by affecting secondary structure and/or protein binding.
Allele-specific protein binding can be tested by RNA
mobility shift assays, in vitro assays that do not require
prior knowledge of the bound proteins. Alternatively, if
the RNA-binding protein is known or predicted, RNA
immunoprecipitation (RIP) using an antibody against the
RNA-binding protein could be performed and allele-
specific binding could be assessed. Interestingly, using
RIP, Olshavsky et al. showed that allele-specific binding
of the RNA-binding protein SRSF1 (also known as ASF/
SF2) affects the splicing of CCND1;89 such a mechanism
could also apply to lncRNAs. It is also possible that genetic
variants within the transcript could affect the stability of
the lncRNA.90
Epigenetic Contribution to Complex Traits
Epigenetic modifications represent an additional layer of
complexity to understanding gene regulation and might
explain some of the failure to identify target genes of
complex diseases. Epigenetic changes such as DNA
methylation and histone modifications are required for
normal gene regulation and are therefore obvious candi-
date targets for GWAS associations.91 DNA methylation is
perhaps the most extensively studied epigenetic modifica-
tion. Aberrant promoter methylation of tumor-suppressor
genes is frequently observed in cancer and firmly
established as an important mechanism for gene inactiva-
tion.92 Although not well understood, gene-body methyl-
ation can suppress transcriptional noise and might also
be involved in splicing regulation.93 Evaluating the link
among genetic variants, DNA methylation, and disease
predisposition is currently a very active area in research.
There are several examples of cis-acting genetic alterations
giving rise to epimutations. In hereditary nonpolyposis
colorectal cancer, MLH1 (MIM 120436) hypermethylation
and transcriptional silencing have been linked to a SNP
within its 50 UTR.94 Similarly, heritable DAPK1 (MIM
600831) methylation in individuals with familial chronic
lymphocytic leukemia is associated with a point mutation
upstream of its promoter.95 Moreover, there is also
evidence that altered DNA methylation of distal transcrip-
tional enhancers might also play a role in cancer predispo-The Americansition.96 Further insight into this potentially causative
relationship has beenmade possible with the development
of high-throughput DNA methylation arrays.97 Similar to
eQTL, methylation quantitative-trait loci (metQTL) can
be used for associating SNPs with CpG methylation in
any tissue or cell type of interest. Most studies to date
have found that correlations with cis-genotypes are more
frequent, but there is also some evidence of trans-
regulation cross multiple tissues.98
Risk-associated SNPs can also disrupt the structural
organization of chromatin in the nucleus. Chromatin-
state signatures correlate with tissue-specific gene expres-
sion; therefore, allelic differences in chromatin could
potentially change expression patterns. Consistent with
this, changes in allele-specific binding of CTCF (an
important chromatin organizer) can affect the expression
of several genes in the ORMDL3 locus and contribute to
the risk of asthma and autoimmune disease.19 Further-
more, common variants at TCF7L2 (MIM 602228) confer
risk of type 2 diabetes (MIM 125852) by altering cis-
regulation and local chromatin structure in islet cells.99
In addition, Cowper-Sal-lari et al. recently used a system-
atic approach to explore the effect of genetic variation on
allele-specific TF binding and chromatin structure. They
showed that the majority of SNPs associated with breast
cancer risk are enriched with FOXA1- and ER-binding
sites, as well as H3K4me1 histone modification.100
FOXA1 is a pioneer factor central for opening compacted
chromatin, nucleosome repositioning, and ER function.
These studies further emphasize the complexity of regula-
tory variation.
The clear relationship between genetic and epigenetic
variation for complex diseases has provided a strong
argument for integrating GWASs with epigenome-wide
association studies (EWASs). As the name suggests, EWASs
utilize large-scale epidemiologic studies and high-
throughput arrays as an unbiased strategy to systematically
study epigenetic control.101 Currently, DNA methylation
is the most suitable mark for EWASs and has been used,
with some success, in the study of both nonmalignant dis-
eases and epigenetic perturbations in cancer. It should be
noted, though, that like GWASs, EWASs have a number
of limitations and considerations in both their design
and their interpretation. Some of the main challenges
include the choice of tissue to be sampled and the matter
of tissue heterogeneity, obtaining adequate sample size
for achieving the necessary statistical power, and replica-
tion in independent study populations. Environmental
factors are another variable because they can also directly
or indirectly induce epigenetic changes.102 Despite these
issues, Bell et al. successfully combined GWAS and EWAS
data to identify variant-CpG-restricted haplotype-specific
methylation within the FTO (MIM 610966) obesity suscep-
tibility locus.103 Their study highlights the potential for
integrating genetic and epigenomic approaches as a post-
GWAS strategy for dissecting the functional consequences
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In Vitro and In Vivo Models for Assessing SNP
Function
The approaches described above only identify candidate
target genes. The next step in the functional analysis pipe-
line is to validate each gene and to explore the funda-
mental mechanisms of disease (Figure 1). Human disease
models can be based on either in vitro studies in cultured
cell lines and/or primary tissues or in vivo models of
disease development. Established human cancer cell lines
have been extensively used for testing the function of
candidate genes at risk loci. The primary advantages of
these models are their ease of manipulation, homogeneity,
and extended replicative capacity. Furthermore, hundreds
of cell lines representing the major forms of cancer are
commercially available, and many of them have been
genetically characterized.104 However, some important
limitations must be recognized, especially when these
models are used for studying genetic associations. The
most relevant limitation is that any functional effects
could be obscured or falsely elevated by cellular genomic
instability. In addition, karyotypic abnormalities and
variability due to extensive passaging and different culture
conditions must also be considered. Better models for
evaluating GWAS-identified genetic variations are normal,
nonaberrant tissues and cell lines. The main challenges
impeding the establishment of these in vitro models are
limited access to clinical samples and difficulties in
culturing and manipulating primary cells. However,
several reasonable models of normal tissue, including
MCF10As for breast, PNT2 for prostate, EndoC-bH1 for
pancreatic beta cells, and lymphoblastoid cell lines for
blood traits, are already available.
Ideally, we need to create panels of genetically matched
‘‘normal cells’’ to provide isogenic systems to study disease
mechanisms. Significant progress toward reaching this
goal has been made with the development of program-
mable nucleases, such as zinc finger nucleases (ZFNs) and
transcription-activator-like effector nucleases (TALENS),
which are promising new tools that enable targeted
genome modifications.105,106 In a genome, these enzymes
induce site-specific double-strand breaks (DSBs), which
cells then respond to with various repair mechanisms.
Many types of genomic alterations, including point
mutations, can be introduced with ZFNs or TALENs, thus
potentially enabling studies to determine the functional
significance of individual sequence variants. There are
several recent examples of interrogation of putative causal
genes in appropriate human cell types. For example,
Soldner et al. used engineered ZFNs to generate isogenic
pluripotent stem cells to study risk variants for Parkinson
disease (MIM 168600).107 The lines differed by two single
point mutations in a-synuclein (MIM 163890) but main-
tained a pluripotent state, the ability to form teratomas,
and the ability to differentiate into dopaminergic neurons
in vitro. Another technical challenge for post-GWAS
research is the difficulty of studying locus heterogeneity,
the joint effect of multiple independent variants across790 The American Journal of Human Genetics 93, 779–797, Novembdifferent loci. This limitation might soon be overcome by
means of an alternative genome editing system called
CRISPR/Cas (Clustered Regularly Interspaced Short
Palindromic Repeats),108 which relies on the RNA-guided
DNA endonuclease, Cas9, inducing targeted DSBs into
genomic DNA. The method also allows for the simulta-
neous introduction of multiple guide RNAs, resulting in
multiplex genome editing in mammalian cells,109 pro-
viding proof of principle of the potential of this system
for GWAS functional studies.
Currently, one of the biggest challenges in post-GWAS
validation is being able to accurately evaluate the effects
of SNPs and their associated genes in an intact organism.
The mouse is usually the mammalian model of choice
because of its high degree of genome similarity, numerous
techniques for genetic manipulation, and capacity to
mimic human multifactorial disease phenotypes.110
Mouse models have mainly been used for studying the
function of the most compelling or nearest candidate
gene to the GWAS SNP for a range of complex diseases.
For example, GWAS-identified SNPs in the vicinity of
NR5A2 (MIM 604453) are associated with pancreatic
cancer (MIM 260350) risk.111 Two recent papers used
loss-of-function mouse models to show that NR5A2 is a
key regulator of pancreatic acinar cell plasticity and that
loss of NR5A2 cooperates with KRAS in preneoplastic trans-
formation of the pancreas.112,113 However, a caveat for
many of these studies is the lack of evidence linking the
functional SNPs to expression of candidate target genes.
This issue has been partly addressed for the 8q24 suscepti-
bility locus. Several studies have indicated that the 8q24
cancer risk SNP rs6983267 resides in an enhancer element
(called MYC-335) that can control expression of the
oncogene c-MYC.10,114 Sur et al. subsequently generated
Myc-335-knockout mice and showed a modest decrease
in c-MYC in the colon, but more interestingly, these
mice were resistant to intestinal tumorigenesis when
challenged with the APCmin (MIM 611731) mutation.115
Although these results clearly show the importance of
the MYC-335 region in intestinal tumorigenesis, the rele-
vance of c-MYC itself remains uncertain, and they also
highlight the need for unbiased approaches to identifying
target gene(s).
As discussed earlier, because most disease-associated
SNPs confer only modest effects on risk, the relevance of
a complete versus heterozygous knockout must always be
considered. TALEN-, ZFN-, and CRISPR/Cas-basedmethods
are themost promising approaches to addressing heterozy-
gous allele combinations. Indeed, these technologies have
already successfully generated monoallelic and biallelic
modifications in mice.116 Currently, only one group has
used ZFNs to study GWAS loci;99 however, the speed
with which ZNF-, TALEN-, and CRISPR/Cas-engineered
mice can be created will greatly accelerate GWAS-driven
functional research. It should be noted that there are
some important ‘‘mouse traps’’ that should be considered
when mouse models are used for delineating humaner 7, 2013
genotype-phenotype relationships. These include species-
species differences in gene function, poor evolutionary
conservation in noncoding regions, changes in cellular
microenvironments and immunity, the genetic back-
ground of the mice, and the presence of specific micro-
biota.110 Future mouse models will also most likely require
a more thorough mapping of the genetic variants already
present and the introduction ofmultiple genetic variations
to the model so that the human genetic landscape can be
more faithfully recapitulated.
Zebrafish and Drosophila are other increasingly popular
model organisms for studying the functions of normal
and disease-associated alleles. Both models have a number
of advantages for post-GWAS analysis over their rodent
counterparts; these include the ease of genetic manipula-
tion, the ability to rapidly produce large numbers of organ-
isms of a specific genotype, and the capacity to study
tissue-specific gene expression in live animals. Again,
most studies to date have used these organisms to study
the function of the nearest candidate gene(s) to the
sentinel SNP without first establishing that the gene is
the target of that SNP.117 For zebrafish, transient disruption
of normal gene function can be achieved by microinjec-
tion of mRNA, DNA, or morpholinos into early
embryos.35 Although not as straightforward, regulatory
elements can also be assessed by the generation of trans-
genic zebrafish by means of reporter constructs.118 In
Drosophila, transgenic RNAi is the most common method
used for downregulating orthologs of candidate genes.119
A disadvantage of using nonmammalian animals to model
human disease is the need for functionally similar ortho-
logs. A recent study attempted to address this limitation
by performing post-GWAS functional assays in both zebra-
fish and Drosophila.120 Of the 49 candidate genes, results
were available for the orthologs of 12 genes in zebrafish
and 25 genes in Drosophila, and orthologs from six genes
were available in both species.120 Clearly, not all down-
stream mechanistic studies will be feasible in these organ-
isms, but for many of the simpler in vitro strategies we
have described, they could help prioritize hypotheses for
testing in more complex organisms.
Conclusions
GWASs have robustly identified thousands of disease- and
trait-associated genetic variants. However, significant
obstacles have hampered our ability to pinpoint casual
variants, identify genes affected by causal variants, and
disentangle the mechanism by which genotype influences
phenotype. The critical first step is to undertake mapping
at increased marker density with imputation to capture
all nongenotyped alleles, which is vital to clarifying the
most likely causal candidates prior to assessment of
whether they contribute to a molecular mechanism.
Even then, it should be noted that variants are unlikely
to act alone, and the importance of combinatorial effects
should be considered. In addition, consistency in the direc-
tion of the effect detected in genetic analyses (e.g.,The Americanincreased or decreased risk) and the probable mechanism
(e.g., upregulation or downregulation of transcription) is
ultimately required for adequately explaining the mole-
cular association, although unknown and surprising gene
functions should always be anticipated.
The emergence of several large-scale genomic data sets
generated by projects such as ENCODE have revolu-
tionized our ability to query and annotate putative cis-
regulatory variants and form readily testable hypotheses.
Expansion of these resources and establishing well-
powered eQTL databases derived from relevant tissues
and cells will enable studies to pinpoint likely causal vari-
ants at any locus. We emphasize that functional studies
must then be undertaken in an unbiased manner so that
undermining the agnostic approach of GWASs can be
avoided. Most reports have simply implicated the nearest
gene to a GWAS hit without any evidence that it is the
true target of the functional variant. This is particularly
relevant for regulatory variants that could be considerably
distant from target gene(s). New technologies, including
3C-based techniques and the use of TALENS and ZFNs for
generating isogenic cell lines, will clearly be important
for identifying and validating the gene(s) directly affected
by the risk-associated variants. Modeling the effect of vali-
dated variants in laboratory animals might then provide
avenues for studying genetic disease.
This review provides a functional pipeline for the iden-
tification of candidate causal variants at GWAS loci. It is
important to note, however, that it is difficult to unequiv-
ocally prove that a SNP is the direct cause of any given
association. As opposed to linking rare mutations to dis-
ease, proving that common variants exert deleterious
effects is problematic. Although experimental evidence
might strongly support a plausible mechanism for an
association, it is unlikely that definitive proof of causality,
equivalent to ‘‘Koch’s postulates for genes,’’ will be
achieved.121 Furthermore, it is becoming clear that causal
variants are not always single SNPs acting alone and that
combinations of variants are often required in order for
effects to be explained. SNPs could also act in unantici-
pated cell types or could be involved in as yet undefined
mechanisms.
GWASs have also received criticism for their lack of clin-
ical translation becausemost effect sizes have been deemed
too small to be meaningful. However, individual small
effect sizes (<1.5) represent the reality of common genetic
variation and do not necessarily preclude clinical utility.
For example, the extremely successful cholesterol-lowering
statin drugs target HMGCR, a GWAS hit for circulating
lipid levels.122 This discrepancy occurs because a drug’s
efficacy bears little relation to the degree of genetic varia-
tion in its target gene. Unraveling the complex mecha-
nisms underlying GWAS associations will ultimately
identify important biological pathways that could present
suitable targets for drug development or repositioning of
known therapeutics.123 Steps toward filling this knowledge
gap, as described in this review, will bring us closer toJournal of Human Genetics 93, 779–797, November 7, 2013 791
elucidating the genetic basis of complex disease and offer
opportunities for personalized medicine.Acknowledgments
We would like to thank Georgia Chenevix-Trench, Dylan Glubb,
and Karen McCue for critical reading of the manuscript. This
work was supported by Australian National Health and Medical
Research Council grants 1021731 (to S.L.E. and J.D.F.) and
1012023 (to J.B.). S.L.E. and J.D.F. were supported by fellowships
from the National Breast Cancer Foundation Australia. A.M.D.
was funded by Cancer Research UK (C8197/A10865) and the
Joseph Mitchell trust. Fine-scale mapping in her laboratory was
funded by Cancer Research UK grants (C1287/A10118) and
(C8197/A10123) and European Commission Seventh Framework
Programme Health-F2-2009-223175 ‘‘COGS’’ WP4 ‘‘Genomic Lo-
cus Mapping.’’ The funders had no role in study design, decision
to publish, or preparation of the manuscript.Web Resources
The URLs for data presented herein are as follows:
1000 Genomes, http://browser.1000genomes.org/index.html
The Cancer Genome Atlas, http://cancergenome.nih.gov/
ChIA-PET Browser, http://cms1.gis.a-star.edu.sg/index.php
ChromHMM, http://compbio.mit.edu/ChromHMM/
ChroMoS, http://epicenter.immunbio.mpg.de/services/chromos
Collaborative Oncological Gene-environment Study, http://www.
nature.com/icogs/
ENCODE, http://www.genome.gov/10005107
EpiGRAPH, http://epigraph.mpi-inf.mpg.de/WebGRAPH/
FunciSNP, http://bioconductor.org/packages/2.12/bioc/html/
FunciSNP.html
Galaxy, https://usegalaxy.org/
Gene Expression Omnibus (GEO), http://www.ncbi.nlm.nih.gov/
geo/
GeneVar, http://www.sanger.ac.uk/resources/software/genevar/
GTEx (Genotype-Tissue Expression) eQTL Browser, http://www.
ncbi.nlm.nih.gov/gtex
GWAS3D, http://jjwanglab.org/gwas3d/
HaploReg, http://www.broadinstitute.org/mammals/haploreg
IMPUTE2, http://mathgen.stats.ox.ac.uk/impute/impute_v2.html
JASPAR, http://jaspar.binf.ku.dk/
LocusZoom, http://csg.sph.umich.edu/locuszoom/
MAPPER2, http://genome.ufl.edu/mapperdb
MethDB, http://www.methdb.de
National Center for Biotechnology Information, http://www.ncbi.
nlm.nih.gov/
NHGRI GWAS Catalog, http://www.genome.gov/GWAstudies
Nuclear Receptor Cistrome, http://www.cistrome.org/Cistrome/
Cistrome_Project.html
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org/
PicTar, http://pictar.mdc-berlin.de/
RegulomeDB, http://www.regulomedb.org
NIH Roadmap Epigenomics Project, http://www.
roadmapepigenomics.org/
Segway, http://noble.gs.washington.edu/proj/segway/
TargetScan 6.2, http://www.targetscan.org/
TRANSFAC, http://www.biobase-international.com/gene-regulation
UCSC Genome Browser, http://genome.ucsc.edu792 The American Journal of Human Genetics 93, 779–797, NovembReferences
1. Hindorff, L.A., MacArthur, J., Morales, J., Junkins, H.A., Hall,
P.N., Klemm, A.K., andManolio, T.A. A Catalog of Published
Genome-Wide Association Studies. http://www.genome.
gov/gwastudies.
2. Kruglyak, L. (1999). Prospects for whole-genome linkage
disequilibrium mapping of common disease genes. Nat.
Genet. 22, 139–144.
3. Cooper, G.M., and Shendure, J. (2011). Needles in stacks of
needles: finding disease-causal variants in a wealth of
genomic data. Nat. Rev. Genet. 12, 628–640.
4. Musunuru, K., Strong, A., Frank-Kamenetsky, M., Lee, N.E.,
Ahfeldt, T., Sachs, K.V., Li, X., Li, H., Kuperwasser, N., Ruda,
V.M., et al. (2010). From noncoding variant to phenotype
via SORT1 at the 1p13 cholesterol locus. Nature 466,
714–719.
5. Bauer, D.E., Kamran, S.C., Lessard, S., Xu, J., Fujiwara, Y.,
Lin, C., Shao, Z., Canver, M.C., Smith, E.C., Pinello, L.,
et al. (2013). An erythroid enhancer of BCL11A subject to
genetic variation determines fetal hemoglobin level. Science
342, 253–257.
6. Zhou, X., Baron, R.M., Hardin, M., Cho, M.H., Zielinski, J.,
Hawrylkiewicz, I., Sliwinski, P., Hersh, C.P., Mancini, J.D.,
Lu, K., et al. (2012). Identification of a chronic obstructive
pulmonary disease genetic determinant that regulates
HHIP. Hum. Mol. Genet. 21, 1325–1335.
7. Nguyen, H.H., Takata, R., Akamatsu, S., Shigemizu, D., Tsu-
noda, T., Furihata, M., Takahashi, A., Kubo, M., Kamatani,
N., Ogawa, O., et al. (2012). IRX4 at 5p15 suppresses pros-
tate cancer growth through the interaction with vitamin
D receptor, conferring prostate cancer susceptibility. Hum.
Mol. Genet. 21, 2076–2085.
8. Bojesen, S.E., Pooley, K.A., Johnatty, S.E., Beesley, J., Michai-
lidou, K., Tyrer, J.P., Edwards, S.L., Pickett, H.A., Shen, H.C.,
Smart, C.E., et al.; Australian Cancer Study; Australian
Ovarian Cancer Study; Kathleen Cuningham Foundation
Consortium for Research into Familial Breast Cancer
(kConFab); Gene Environment Interaction and Breast
Cancer (GENICA); Swedish Breast Cancer Study
(SWE-BRCA); Hereditary Breast and Ovarian Cancer
Research Group Netherlands (HEBON); Epidemiological
study of BRCA1 & BRCA2 Mutation Carriers (EMBRACE);
Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation
Carriers (GEMO) (2013). Multiple independent variants at
the TERT locus are associated with telomere length and
risks of breast and ovarian cancer. Nat. Genet. 45, 371–
384, e1–e2.
9. Pittman, A.M., Naranjo, S., Jalava, S.E., Twiss, P., Ma, Y.,
Olver, B., Lloyd, A., Vijayakrishnan, J., Qureshi, M.,
Broderick, P., et al. (2010). Allelic variation at the 8q23.3
colorectal cancer risk locus functions as a cis-acting regu-
lator of EIF3H. PLoS Genet. 6, e1001126.
10. Tuupanen, S., Turunen, M., Lehtonen, R., Hallikas, O.,
Vanharanta, S., Kivioja, T., Bjo¨rklund, M., Wei, G., Yan, J.,
Niittyma¨ki, I., et al. (2009). The common colorectal cancer
predisposition SNP rs6983267 at chromosome 8q24
confers potential to enhanced Wnt signaling. Nat. Genet.
41, 885–890.
11. Wright, J.B., Brown, S.J., and Cole, M.D. (2010). Upre-
gulation of c-MYC in cis through a large chromatin loop
linked to a cancer risk-associated single-nucleotideer 7, 2013
polymorphism in colorectal cancer cells. Mol. Cell. Biol. 30,
1411–1420.
12. Ahmadiyeh, N., Pomerantz, M.M., Grisanzio, C., Herman, P.,
Jia, L., Almendro, V., He, H.H., Brown, M., Liu, X.S., Davis,
M., et al. (2010). 8q24 prostate, breast, and colon cancer
risk loci show tissue-specific long-range interaction with
MYC. Proc. Natl. Acad. Sci. USA 107, 9742–9746.
13. Sotelo, J., Esposito, D., Duhagon, M.A., Banfield, K.,
Mehalko, J., Liao, H., Stephens, R.M., Harris, T.J., Munroe,
D.J., andWu, X. (2010). Long-range enhancers on 8q24 regu-
late c-Myc. Proc. Natl. Acad. Sci. USA 107, 3001–3005.
14. Harismendy, O., Notani, D., Song, X., Rahim, N.G., Tanasa,
B., Heintzman, N., Ren, B., Fu, X.D., Topol, E.J., Rosenfeld,
M.G., and Frazer, K.A. (2011). 9p21 DNA variants associated
with coronary artery disease impair interferon-g signalling
response. Nature 470, 264–268.
15. Visel, A., Zhu, Y., May, D., Afzal, V., Gong, E., Attanasio, C.,
Blow, M.J., Cohen, J.C., Rubin, E.M., and Pennacchio, L.A.
(2010). Targeted deletion of the 9p21 non-coding coronary
artery disease risk interval in mice. Nature 464, 409–412.
16. Meyer, K.B., Maia, A.T., O’Reilly, M., Teschendorff, A.E.,
Chin, S.F., Caldas, C., and Ponder, B.A. (2008). Allele-specific
up-regulation of FGFR2 increases susceptibility to breast can-
cer. PLoS Biol. 6, e108.
17. French, J.D., Ghoussaini, M., Edwards, S.L., Meyer, K.B.,
Michailidou, K., Ahmed, S., Khan, S., Maranian, M.J.,
O’Reilly, M., Hillman, K.M., et al.; GENICA Network;
kConFab Investigators (2013). Functional variants at the
11q13 risk locus for breast cancer regulate cyclin D1 expres-
sion through long-range enhancers. Am. J. Hum. Genet.
92, 489–503.
18. Scho¨del, J., Bardella, C., Sciesielski, L.K., Brown, J.M., Pugh,
C.W., Buckle, V., Tomlinson, I.P., Ratcliffe, P.J., and Mole,
D.R. (2012). Common genetic variants at the 11q13.3 renal
cancer susceptibility locus influence binding of HIF to an
enhancer of cyclin D1 expression. Nat. Genet. 44, 420–425,
S1–S2.
19. Verlaan, D.J., Berlivet, S., Hunninghake, G.M., Madore, A.M.,
Larivie`re, M., Moussette, S., Grundberg, E., Kwan, T., Ouimet,
M., Ge, B., et al. (2009). Allele-specific chromatin remodeling
in the ZPBP2/GSDMB/ORMDL3 locus associated with the
risk of asthma and autoimmune disease. Am. J. Hum. Genet.
85, 377–393.
20. Zhang, X., Cowper-Sal lari, R., Bailey, S.D., Moore, J.H., and
Lupien,M. (2012). Integrative functional genomics identifies
an enhancer looping to the SOX9 gene disrupted by
the 17q24.3 prostate cancer risk locus. Genome Res. 22,
1437–1446.
21. Hirschhorn, J.N., andDaly, M.J. (2005). Genome-wide associ-
ation studies for common diseases and complex traits. Nat.
Rev. Genet. 6, 95–108.
22. Reich, D.E., Cargill, M., Bolk, S., Ireland, J., Sabeti, P.C.,
Richter, D.J., Lavery, T., Kouyoumjian, R., Farhadian, S.F.,
Ward, R., and Lander, E.S. (2001). Linkage disequilibrium in
the human genome. Nature 411, 199–204.
23. Dunning, A.M., Durocher, F., Healey, C.S., Teare, M.D.,
McBride, S.E., Carlomagno, F., Xu, C.F., Dawson, E., Rhodes,
S., Ueda, S., et al. (2000). The extent of linkage disequilibrium
in four populations with distinct demographic histories. Am.
J. Hum. Genet. 67, 1544–1554.
24. Udler, M.S., Ahmed, S., Healey, C.S., Meyer, K., Struewing, J.,
Maranian, M., Kwon, E.M., Zhang, J., Tyrer, J., Karlins, E.,The Americanet al. (2010). Fine scale mapping of the breast cancer 16q12
locus. Hum. Mol. Genet. 19, 2507–2515.
25. Abecasis, G.R., Auton, A., Brooks, L.D., DePristo, M.A.,
Durbin, R.M., Handsaker, R.E., Kang, H.M., Marth, G.T.,
and McVean, G.A.; 1000 Genomes Project Consortium
(2012). An integrated map of genetic variation from 1,092
human genomes. Nature 491, 56–65.
26. Galvin, B.D., Hart, K.C., Meyer, A.N., Webster, M.K., and
Donoghue, D.J. (1996). Constitutive receptor activation by
Crouzon syndrome mutations in fibroblast growth factor
receptor (FGFR)2 and FGFR2/Neu chimeras. Proc. Natl.
Acad. Sci. USA 93, 7894–7899.
27. Dutt, A., Salvesen, H.B., Chen, T.H., Ramos, A.H., Onofrio,
R.C., Hatton, C., Nicoletti, R., Winckler, W., Grewal, R.,
Hanna, M., et al. (2008). Drug-sensitive FGFR2 mutations
in endometrial carcinoma. Proc. Natl. Acad. Sci. USA 105,
8713–8717.
28. Trynka, G., Hunt, K.A., Bockett, N.A., Romanos, J., Mistry, V.,
Szperl, A., Bakker, S.F., Bardella, M.T., Bhaw-Rosun, L., Castil-
lejo, G., et al.; Spanish Consortium on the Genetics of
Coeliac Disease (CEGEC); PreventCD Study Group; Well-
come Trust Case Control Consortium (WTCCC) (2011).
Dense genotyping identifies and localizes multiple common
and rare variant association signals in celiac disease. Nat.
Genet. 43, 1193–1201.
29. Voight, B.F., Kang, H.M., Ding, J., Palmer, C.D., Sidore, C.,
Chines, P.S., Burtt, N.P., Fuchsberger, C., Li, Y., Erdmann, J.,
et al. (2012). The metabochip, a custom genotyping array
for genetic studies of metabolic, cardiovascular, and anthro-
pometric traits. PLoS Genet. 8, e1002793.
30. Michailidou, K., Hall, P., Gonzalez-Neira, A., Ghoussaini, M.,
Dennis, J., Milne, R.L., Schmidt, M.K., Chang-Claude, J.,
Bojesen, S.E., Bolla, M.K., et al.; Breast and Ovarian Cancer
Susceptibility Collaboration; Hereditary Breast and Ovarian
Cancer Research Group Netherlands (HEBON); kConFab
Investigators; Australian Ovarian Cancer Study Group;
GENICA (Gene Environment Interaction and Breast Cancer
in Germany) Network (2013). Large-scale genotyping iden-
tifies 41 new loci associated with breast cancer risk. Nat.
Genet. 45, 353–361, e1–e2.
31. Udler, M.S., Tyrer, J., and Easton, D.F. (2010). Evaluating the
power to discriminate between highly correlated SNPs in
genetic association studies. Genet. Epidemiol. 34, 463–468.
32. Chatterjee, N., Chen, Y.H., Luo, S., and Carroll, R.J. (2009).
Analysis of Case-Control Association Studies: SNPs, Imputa-
tion and Haplotypes. Stat. Sci. 24, 489–502.
33. Turnbull, C., Ahmed, S., Morrison, J., Pernet, D., Renwick, A.,
Maranian, M., Seal, S., Ghoussaini, M., Hines, S., Healey, C.S.,
et al.; Breast Cancer Susceptibility Collaboration (UK) (2010).
Genome-wide association study identifies five new breast
cancer susceptibility loci. Nat. Genet. 42, 504–507.
34. Crowther-Swanepoel, D., Broderick, P., Ma, Y., Robertson, L.,
Pittman, A.M., Price, A., Twiss, P., Vijayakrishnan, J., Qureshi,
M., Dyer, M.J., et al. (2010). Fine-scalemapping of the 6p25.3
chronic lymphocytic leukaemia susceptibility locus. Hum.
Mol. Genet. 19, 1840–1845.
35. Sexton, T., Bantignies, F., and Cavalli, G. (2009). Genomic
interactions: chromatin loops and gene meeting points
in transcriptional regulation. Semin. Cell Dev. Biol. 20,
849–855.
36. Udler, M.S., Meyer, K.B., Pooley, K.A., Karlins, E., Struewing,
J.P., Zhang, J., Doody, D.R., MacArthur, S., Tyrer, J., Pharoah,Journal of Human Genetics 93, 779–797, November 7, 2013 793
P.D., et al.; SEARCH Collaborators (2009). FGFR2 variants
and breast cancer risk: fine-scale mapping using African
American studies and analysis of chromatin conformation.
Hum. Mol. Genet. 18, 1692–1703.
37. Ghoussaini, M., Song, H., Koessler, T., Al Olama, A.A.,
Kote-Jarai, Z., Driver, K.E., Pooley, K.A., Ramus, S.J., Kjaer,
S.K., Hogdall, E., et al.; UK Genetic Prostate Cancer Study
Collaborators/British Association of Urological Surgeons’
Section of Oncology; UK ProtecT Study Collaborators
(2008). Multiple loci with different cancer specificities
within the 8q24 gene desert. J. Natl. Cancer Inst. 100,
962–966.
38. Berndt, S.I., Sampson, J., Yeager, M., Jacobs, K.B., Wang, Z.,
Hutchinson, A., Chung, C., Orr, N., Wacholder, S.,
Chatterjee, N., et al. (2011). Large-scale fine mapping of the
HNF1B locus and prostate cancer risk. Hum. Mol. Genet.
20, 3322–3329.
39. Sanna, S., Li, B., Mulas, A., Sidore, C., Kang, H.M., Jackson,
A.U., Piras, M.G., Usala, G., Maninchedda, G., Sassu, A.,
et al. (2011). Fine mapping of five loci associated with
low-density lipoprotein cholesterol detects variants that
double the explained heritability. PLoS Genet. 7, e1002198.
40. Hein, R., Maranian, M., Hopper, J.L., Kapuscinski, M.K.,
Southey, M.C., Park, D.J., Schmidt, M.K., Broeks, A., Hoger-
vorst, F.B., Bueno-de-Mesquita, H.B., et al.; GENICANetwork;
Kconfab Investigators; AOCS Group (2012). Comparison of
6q25 breast cancer hits from Asian and European Genome
Wide Association Studies in the Breast Cancer Association
Consortium (BCAC). PLoS ONE 7, e42380.
41. Manolio, T.A., Collins, F.S., Cox, N.J., Goldstein, D.B.,
Hindorff, L.A., Hunter, D.J., McCarthy, M.I., Ramos, E.M.,
Cardon, L.R., Chakravarti, A., et al. (2009). Finding the
missing heritability of complex diseases. Nature 461,
747–753.
42. Kadonaga, J.T. (2004). Regulation of RNA polymerase II
transcription by sequence-specific DNA binding factors.
Cell 116, 247–257.
43. Strahl, B.D., and Allis, C.D. (2000). The language of covalent
histone modifications. Nature 403, 41–45.
44. Barrett, J.C., Fry, B., Maller, J., and Daly, M.J. (2005). Haplo-
view: analysis and visualization of LD and haplotype maps.
Bioinformatics 21, 263–265.
45. Maurano, M.T., Humbert, R., Rynes, E., Thurman, R.E.,
Haugen, E., Wang, H., Reynolds, A.P., Sandstrom, R., Qu,
H., Brody, J., et al. (2012). Systematic localization of common
disease-associated variation in regulatory DNA. Science 337,
1190–1195.
46. Wang, K., Li, M., and Hakonarson, H. (2010). Analysing
biological pathways in genome-wide association studies.
Nat. Rev. Genet. 11, 843–854.
47. Morley, M., Molony, C.M., Weber, T.M., Devlin, J.L., Ewens,
K.G., Spielman, R.S., and Cheung, V.G. (2004). Genetic anal-
ysis of genome-wide variation in human gene expression.
Nature 430, 743–747.
48. Lappalainen, T., Sammeth, M., Friedla¨nder, M.R., ’t Hoen,
P.A., Monlong, J., Rivas, M.A., Gonza`lez-Porta, M., Kurba-
tova, N., Griebel, T., Ferreira, P.G., et al.; Geuvadis
Consortium (2013). Transcriptome and genome sequencing
uncovers functional variation in humans. Nature 501,
506–511.
49. Nicolae, D.L., Gamazon, E., Zhang, W., Duan, S., Dolan,
M.E., and Cox, N.J. (2010). Trait-associated SNPs are more794 The American Journal of Human Genetics 93, 779–797, Novemblikely to be eQTLs: annotation to enhance discovery from
GWAS. PLoS Genet. 6, e1000888.
50. Dimas, A.S., Deutsch, S., Stranger, B.E., Montgomery, S.B.,
Borel, C., Attar-Cohen, H., Ingle, C., Beazley, C., Gutierrez
Arcelus, M., Sekowska, M., et al. (2009). Common regulatory
variation impacts gene expression in a cell type-dependent
manner. Science 325, 1246–1250.
51. Li, Q., Seo, J.H., Stranger, B., McKenna, A., Pe’er, I.,
Laframboise, T., Brown, M., Tyekucheva, S., and Freedman,
M.L. (2013). Integrative eQTL-based analyses reveal the
biology of breast cancer risk loci. Cell 152, 633–641.
52. Curtis, C., Shah, S.P., Chin, S.F., Turashvili, G., Rueda, O.M.,
Dunning, M.J., Speed, D., Lynch, A.G., Samarajiwa, S.,
Yuan, Y., et al.; METABRIC Group (2012). The genomic
and transcriptomic architecture of 2,000 breast tumours
reveals novel subgroups. Nature 486, 346–352.
53. Nica, A.C., Parts, L., Glass, D., Nisbet, J., Barrett, A., Sekowska,
M., Travers, M., Potter, S., Grundberg, E., Small, K., et al.;
MuTHER Consortium (2011). The architecture of gene regu-
latory variation across multiple human tissues: the MuTHER
study. PLoS Genet. 7, e1002003.
54. Fu, J., Wolfs, M.G., Deelen, P., Westra, H.J., Fehrmann,
R.S., Te Meerman, G.J., Buurman, W.A., Rensen, S.S.,
Groen, H.J., Weersma, R.K., et al. (2012). Unraveling
the regulatory mechanisms underlying tissue-dependent
genetic variation of gene expression. PLoS Genet. 8,
e1002431.
55. Brown, C.D., Mangravite, L.M., and Engelhardt, B.E. (2013).
Integrative modeling of eQTLs and cis-regulatory elements
suggests mechanisms underlying cell type specificity of
eQTLs. PLoS Genet. 9, e1003649.
56. Zeller, T., Wild, P., Szymczak, S., Rotival, M., Schillert, A.,
Castagne, R., Maouche, S., Germain, M., Lackner, K., Ross-
mann, H., et al. (2010). Genetics and beyond—the transcrip-
tome of human monocytes and disease susceptibility. PLoS
ONE 5, e10693.
57. Myers, A.J., Gibbs, J.R., Webster, J.A., Rohrer, K., Zhao, A.,
Marlowe, L., Kaleem, M., Leung, D., Bryden, L., Nath, P.,
et al. (2007). A survey of genetic human cortical gene expres-
sion. Nat. Genet. 39, 1494–1499.
58. Cheung, V.G., and Spielman, R.S. (2009). Genetics of human
gene expression: mapping DNA variants that influence gene
expression. Nat. Rev. Genet. 10, 595–604.
59. Westra, H.J., Peters, M.J., Esko, T., Yaghootkar, H.,
Schurmann, C., Kettunen, J., Christiansen, M.W., Fairfax,
B.P., Schramm, K., Powell, J.E., et al. (2013). Systematic
identification of trans eQTLs as putative drivers of known
disease associations. Nat. Genet. 45, 1238–1243.
60. Fehrmann, R.S., Jansen, R.C., Veldink, J.H., Westra, H.J.,
Arends, D., Bonder, M.J., Fu, J., Deelen, P., Groen, H.J.,
Smolonska, A., et al. (2011). Trans-eQTLs reveal that
independent genetic variants associated with a complex
phenotype converge on intermediate genes, with a major
role for the HLA. PLoS Genet. 7, e1002197.
61. Garnier, S., Truong, V., Brocheton, J., Zeller, T., Rovital, M.,
Wild, P.S., Ziegler, A., Munzel, T., Tiret, L., Blankenberg, S.,
et al.; Cardiogenics Consortium (2013). Genome-wide haplo-
type analysis of cis expression quantitative trait loci inmono-
cytes. PLoS Genet. 9, e1003240.
62. Kumar, V., Westra, H.J., Karjalainen, J., Zhernakova, D.V.,
Esko, T., Hrdlickova, B., Almeida, R., Zhernakova, A., Rein-
maa, E., Vo˜sa, U., et al. (2013). Human disease-associateder 7, 2013
genetic variation impacts large intergenic non-coding RNA
expression. PLoS Genet. 9, e1003201.
63. Lalonde, E., Ha, K.C., Wang, Z., Bemmo, A., Kleinman, C.L.,
Kwan, T., Pastinen, T., and Majewski, J. (2011). RNA
sequencing reveals the role of splicing polymorphisms
in regulating human gene expression. Genome Res. 21,
545–554.
64. Pai, A.A., Cain, C.E., Mizrahi-Man, O., De Leon, S., Lewellen,
N., Veyrieras, J.B., Degner, J.F., Gaffney, D.J., Pickrell, J.K.,
Stephens, M., et al. (2012). The contribution of RNA decay
quantitative trait loci to inter-individual variation in
steady-state gene expression levels. PLoS Genet. 8, e1003000.
65. Stranger, B.E., Montgomery, S.B., Dimas, A.S., Parts, L.,
Stegle, O., Ingle, C.E., Sekowska, M., Smith, G.D., Evans,
D., Gutierrez-Arcelus, M., et al. (2012). Patterns of cis regula-
tory variation in diverse human populations. PLoS Genet. 8,
e1002639.
66. Wu, L., Candille, S.I., Choi, Y., Xie, D., Jiang, L., Li-Pook-
Than, J., Tang, H., and Snyder, M. (2013). Variation and
genetic control of protein abundance in humans. Nature
499, 79–82.
67. Dekker, J., Rippe, K., Dekker, M., and Kleckner, N. (2002).
Capturing chromosome conformation. Science 295, 1306–
1311.
68. Sanyal, A., Lajoie, B.R., Jain, G., and Dekker, J. (2012). The
long-range interaction landscape of gene promoters. Nature
489, 109–113.
69. Patel, B., Kang, Y., Cui, K., Litt, M., Riberio, M.S., Deng, C.,
Salz, T., Casada, S., Fu, X., Qiu, Y., et al. (2013). Aberrant
TAL1 activation is mediated by an interchromosomal inter-
action in human T-cell acute lymphoblastic leukemia. Leuke-
mia. Published online May 23, 2013.
70. Dostie, J., Richmond, T.A., Arnaout, R.A., Selzer, R.R., Lee,
W.L., Honan, T.A., Rubio, E.D., Krumm, A., Lamb, J.,
Nusbaum, C., et al. (2006). Chromosome Conformation
Capture Carbon Copy (5C): a massively parallel solution
for mapping interactions between genomic elements.
Genome Res. 16, 1299–1309.
71. Fullwood, M.J., Liu, M.H., Pan, Y.F., Liu, J., Xu, H., Mohamed,
Y.B., Orlov, Y.L., Velkov, S., Ho, A., Mei, P.H., et al. (2009). An
oestrogen-receptor-alpha-bound human chromatin interac-
tome. Nature 462, 58–64.
72. Li, G., Ruan, X., Auerbach, R.K., Sandhu, K.S., Zheng, M.,
Wang, P., Poh, H.M., Goh, Y., Lim, J., Zhang, J., et al.
(2012). Extensive promoter-centered chromatin interactions
provide a topological basis for transcription regulation. Cell
148, 84–98.
73. Chepelev, I., Wei, G., Wangsa, D., Tang, Q., and Zhao, K.
(2012). Characterization of genome-wide enhancer-pro-
moter interactions reveals co-expression of interacting genes
and modes of higher order chromatin organization. Cell Res.
22, 490–503.
74. Handoko, L., Xu, H., Li, G., Ngan, C.Y., Chew, E., Schnapp,
M., Lee, C.W., Ye, C., Ping, J.L., Mulawadi, F., et al. (2011).
CTCF-mediated functional chromatin interactome in plurip-
otent cells. Nat. Genet. 43, 630–638.
75. Rhie, S.K., Coetzee, S.G., Noushmehr, H., Yan, C., Kim, J.M.,
Haiman, C.A., and Coetzee, G.A. (2013). Comprehensive
functional annotation of seventy-one breast cancer risk
Loci. PLoS ONE 8, e63925.
76. Pharoah, P.D., Tsai, Y.Y., Ramus, S.J., Phelan, C.M., Goode,
E.L., Lawrenson, K., Buckley, M., Fridley, B.L., Tyrer, J.P.,The AmericanShen, H., et al.; Australian Cancer Study; Australian Ovarian
Cancer Study Group (2013). GWAS meta-analysis and repli-
cation identifies three new susceptibility loci for ovarian
cancer. Nat. Genet. 45, 362–370, e1–e2.
77. Qiu, X., Vu, T.H., Lu, Q., Ling, J.Q., Li, T., Hou, A.,Wang, S.K.,
Chen, H.L., Hu, J.F., and Hoffman, A.R. (2008). A complex
deoxyribonucleic acid looping configuration associated
with the silencing of the maternal Igf2 allele. Mol. Endocri-
nol. 22, 1476–1488.
78. Barski, A., Cuddapah, S., Cui, K., Roh, T.Y., Schones, D.E.,
Wang, Z., Wei, G., Chepelev, I., and Zhao, K. (2007).
High-resolution profiling of histone methylations in the
human genome. Cell 129, 823–837.
79. Butter, F., Davison, L., Viturawong, T., Scheibe, M., Vermeu-
len, M., Todd, J.A., and Mann, M. (2012). Proteome-wide
analysis of disease-associated SNPs that show allele-specific
transcription factor binding. PLoS Genet. 8, e1002982.
80. Bartel, D.P. (2009). MicroRNAs: target recognition and regu-
latory functions. Cell 136, 215–233.
81. Kulkarni, S., Savan, R., Qi, Y., Gao, X., Yuki, Y., Bass, S.E.,
Martin, M.P., Hunt, P., Deeks, S.G., Telenti, A., et al. (2011).
Differential microRNA regulation of HLA-C expression and
its association with HIV control. Nature 472, 495–498.
82. Thomas, R., Apps, R., Qi, Y., Gao, X., Male, V., O’hUigin, C.,
O’Connor, G., Ge, D., Fellay, J., Martin, J.N., et al. (2009).
HLA-C cell surface expression and control of HIV/AIDS
correlate with a variant upstream of HLA-C. Nat. Genet. 41,
1290–1294.
83. Liu, C., Mallick, B., Long, D., Rennie, W.A., Wolenc, A.,
Carmack, C.S., and Ding, Y. (2013). CLIP-based prediction
of mammalian microRNA binding sites. Nucleic Acids Res.
41, e138.
84. Gamazon, E.R., Ziliak, D., Im, H.K., LaCroix, B., Park, D.S.,
Cox, N.J., and Huang, R.S. (2012). Genetic architecture of mi-
croRNA expression: implications for the transcriptome and
complex traits. Am. J. Hum. Genet. 90, 1046–1063.
85. Richardson, K., Lai, C.Q., Parnell, L.D., Lee, Y.C., and Ordo-
vas, J.M. (2011). A genome-wide survey for SNPs altering
microRNA seed sites identifies functional candidates in
GWAS. BMC Genomics 12, 504.
86. Cunnington, M.S., Santibanez Koref, M., Mayosi, B.M., Burn,
J., and Keavney, B. (2010). Chromosome 9p21 SNPs Associ-
ated withMultiple Disease Phenotypes Correlate with ANRIL
Expression. PLoS Genet. 6, e1000899.
87. Jendrzejewski, J., He, H., Radomska, H.S., Li, W., Tomsic, J.,
Liyanarachchi, S., Davuluri, R.V., Nagy, R., and de la
Chapelle, A. (2012). The polymorphism rs944289 predis-
poses to papillary thyroid carcinoma through a large inter-
genic noncoding RNA gene of tumor suppressor type. Proc.
Natl. Acad. Sci. USA 109, 8646–8651.
88. Mercer, T.R., Gerhardt, D.J., Dinger, M.E., Crawford, J., Trap-
nell, C., Jeddeloh, J.A., Mattick, J.S., and Rinn, J.L. (2012).
Targeted RNA sequencing reveals the deep complexity of
the human transcriptome. Nat. Biotechnol. 30, 99–104.
89. Olshavsky, N.A., Comstock, C.E., Schiewer, M.J., Augello,
M.A., Hyslop, T., Sette, C., Zhang, J., Parysek, L.M., and
Knudsen, K.E. (2010). Identification of ASF/SF2 as a critical,
allele-specific effector of the cyclin D1b oncogene. Cancer
Res. 70, 3975–3984.
90. van Dijk, M., Thulluru, H.K., Mulders, J., Michel, O.J.,
Poutsma, A.,Windhorst, S., Kleiverda, G., Sie, D., Lachmeijer,
A.M., and Oudejans, C.B. (2012). HELLP babies link a novelJournal of Human Genetics 93, 779–797, November 7, 2013 795
lincRNA to the trophoblast cell cycle. J. Clin. Invest. 122,
4003–4011.
91. Petronis, A. (2010). Epigenetics as a unifying principle in
the aetiology of complex traits and diseases. Nature 465,
721–727.
92. Robertson, K.D. (2005). DNA methylation and human dis-
ease. Nat. Rev. Genet. 6, 597–610.
93. Lorincz, M.C., Dickerson, D.R., Schmitt, M., and Groudine,
M. (2004). Intragenic DNA methylation alters chromatin
structure and elongation efficiency in mammalian cells.
Nat. Struct. Mol. Biol. 11, 1068–1075.
94. Hitchins, M.P., Rapkins, R.W., Kwok, C.T., Srivastava, S.,
Wong, J.J., Khachigian, L.M., Polly, P., Goldblatt, J., and
Ward, R.L. (2011). Dominantly inherited constitutional
epigenetic silencing of MLH1 in a cancer-affected family is
linked to a single nucleotide variant within the 5’UTR.
Cancer Cell 20, 200–213.
95. Raval, A., Tanner, S.M., Byrd, J.C., Angerman, E.B., Perko,
J.D., Chen, S.S., Hackanson, B., Grever, M.R., Lucas, D.M.,
Matkovic, J.J., et al. (2007). Downregulation of death-associ-
ated protein kinase 1 (DAPK1) in chronic lymphocytic leuke-
mia. Cell 129, 879–890.
96. Aran, D., Sabato, S., and Hellman, A. (2013). DNA methyl-
ation of distal regulatory sites characterizes dysregulation of
cancer genes. Genome Biol. 14, R21.
97. Kerkel, K., Spadola, A., Yuan, E., Kosek, J., Jiang, L., Hod, E.,
Li, K., Murty, V.V., Schupf, N., Vilain, E., et al. (2008).
Genomic surveys by methylation-sensitive SNP analysis
identify sequence-dependent allele-specific DNA methyl-
ation. Nat. Genet. 40, 904–908.
98. Gibbs, J.R., van der Brug, M.P., Hernandez, D.G., Traynor,
B.J., Nalls, M.A., Lai, S.L., Arepalli, S., Dillman, A., Rafferty,
I.P., Troncoso, J., et al. (2010). Abundant quantitative trait
loci exist for DNA methylation and gene expression in
human brain. PLoS Genet. 6, e1000952.
99. Savic, D., Ye, H., Aneas, I., Park, S.Y., Bell, G.I., and Nobrega,
M.A. (2011). Alterations in TCF7L2 expression define its role
as a key regulator of glucose metabolism. Genome Res. 21,
1417–1425.
100. Cowper-Sal lari, R., Zhang, X., Wright, J.B., Bailey, S.D., Cole,
M.D., Eeckhoute, J., Moore, J.H., and Lupien, M. (2012).
Breast cancer risk-associated SNPs modulate the affinity of
chromatin for FOXA1 and alter gene expression. Nat. Genet.
44, 1191–1198.
101. Rakyan, V.K., Down, T.A., Balding, D.J., and Beck, S. (2011).
Epigenome-wide association studies for common human
diseases. Nat. Rev. Genet. 12, 529–541.
102. Cortessis, V.K., Thomas, D.C., Levine, A.J., Breton, C.V.,
Mack, T.M., Siegmund, K.D., Haile, R.W., and Laird, P.W.
(2012). Environmental epigenetics: prospects for studying
epigenetic mediation of exposure-response relationships.
Hum. Genet. 131, 1565–1589.
103. Bell, C.G., Finer, S., Lindgren, C.M., Wilson, G.A., Rakyan,
V.K., Teschendorff, A.E., Akan, P., Stupka, E., Down, T.A., Pro-
kopenko, I., et al.; International Type 2 Diabetes 1q Con-
sortium (2010). Integrated genetic and epigenetic analysis
identifies haplotype-specific methylation in the FTO type 2
diabetes and obesity susceptibility locus. PLoS ONE 5,
e14040.
104. Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K.,
Margolin, A.A., Kim, S., Wilson, C.J., Leha´r, J., Kryukov,
G.V., Sonkin, D., et al. (2012). The Cancer Cell Line Encyclo-796 The American Journal of Human Genetics 93, 779–797, Novembpedia enables predictive modelling of anticancer drug
sensitivity. Nature 483, 603–607.
105. Urnov, F.D., Rebar, E.J., Holmes,M.C., Zhang, H.S., and Greg-
ory, P.D. (2010). Genome editing with engineered zinc finger
nucleases. Nat. Rev. Genet. 11, 636–646.
106. Miller, J.C., Tan, S., Qiao, G., Barlow, K.A., Wang, J., Xia, D.F.,
Meng, X., Paschon, D.E., Leung, E., Hinkley, S.J., et al. (2011).
A TALE nuclease architecture for efficient genome editing.
Nat. Biotechnol. 29, 143–148.
107. Soldner, F., Laganie`re, J., Cheng, A.W., Hockemeyer, D., Gao,
Q., Alagappan, R., Khurana, V., Golbe, L.I., Myers, R.H., Lind-
quist, S., et al. (2011). Generation of isogenic pluripotent
stem cells differing exclusively at two early onset Parkinson
point mutations. Cell 146, 318–331.
108. Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N.,
Hsu, P.D., Wu, X., Jiang, W., Marraffini, L.A., and Zhang, F.
(2013). Multiplex genome engineering using CRISPR/Cas
systems. Science 339, 819–823.
109. Cho, S.W., Kim, S., Kim, J.M., and Kim, J.S. (2013). Targeted
genome engineering in human cells with the Cas9 RNA-
guided endonuclease. Nat. Biotechnol. 31, 230–232.
110. Ermann, J., and Glimcher, L.H. (2012). After GWAS: mice to
the rescue? Curr. Opin. Immunol. 24, 564–570.
111. Petersen, G.M., Amundadottir, L., Fuchs, C.S., Kraft, P.,
Stolzenberg-Solomon, R.Z., Jacobs, K.B., Arslan, A.A.,
Bueno-de-Mesquita, H.B., Gallinger, S., Gross, M., et al.
(2010). A genome-wide association study identifies pancre-
atic cancer susceptibility loci on chromosomes 13q22.1,
1q32.1 and 5p15.33. Nat. Genet. 42, 224–228.
112. Flandez, M., Cendrowski, J., Can˜amero, M., Salas, A., Del
Pozo, N., Schoonjans, K., and Real, F.X. (2013). Nr5a2 hetero-
zygosity sensitises to, and cooperates with, inflammation in
KRasG12V-driven pancreatic tumourigenesis. Gut. Published
online April 18, 2013.
113. von Figura, G., Morris, J.P., 4th,Wright, C.V., and Hebrok, M.
(2013). Nr5a2 maintains acinar cell differentiation and
constrains oncogenic Kras-mediated pancreatic neoplastic
initiation. Gut. Published online May 3, 2013.
114. Pomerantz, M.M., Ahmadiyeh, N., Jia, L., Herman, P., Verzi,
M.P., Doddapaneni, H., Beckwith, C.A., Chan, J.A., Hills,
A., Davis, M., et al. (2009). The 8q24 cancer risk variant
rs6983267 shows long-range interaction with MYC in
colorectal cancer. Nat. Genet. 41, 882–884.
115. Sur, I.K., Hallikas, O., Va¨ha¨rautio, A., Yan, J., Turunen, M.,
Enge, M., Taipale, M., Karhu, A., Aaltonen, L.A., and Taipale,
J. (2012). Mice lacking a Myc enhancer that includes human
SNP rs6983267 are resistant to intestinal tumors. Science
338, 1360–1363.
116. Sung, Y.H., Baek, I.J., Kim, D.H., Jeon, J., Lee, J., Lee, K.,
Jeong, D., Kim, J.S., and Lee, H.W. (2013). Knockout mice
created by TALEN-mediated gene targeting. Nat. Biotechnol.
31, 23–24.
117. Gieger, C., Radhakrishnan, A., Cvejic, A., Tang, W., Porcu, E.,
Pistis, G., Serbanovic-Canic, J., Elling, U., Goodall, A.H.,
Labrune, Y., et al. (2011). New gene functions in megakaryo-
poiesis and platelet formation. Nature 480, 201–208.
118. Ragvin, A., Moro, E., Fredman, D., Navratilova, P., Drivenes,
O., Engstro¨m, P.G., Alonso, M.E., de la Calle Mustienes, E.,
Go´mez Skarmeta, J.L., Tavares, M.J., et al. (2010). Long-range
gene regulation links genomic type 2 diabetes and obesity
risk regions to HHEX, SOX4, and IRX3. Proc. Natl. Acad.
Sci. USA 107, 775–780.er 7, 2013
119. Dietzl, G., Chen, D., Schnorrer, F., Su, K.C., Barinova, Y., Fell-
ner, M., Gasser, B., Kinsey, K., Oppel, S., Scheiblauer, S., et al.
(2007). A genome-wide transgenic RNAi library for condi-
tional gene inactivation in Drosophila. Nature 448, 151–156.
120. den Hoed, M., Eijgelsheim, M., Esko, T., Brundel, B.J., Peal,
D.S., Evans, D.M., Nolte, I.M., Segre`, A.V., Holm, H.,
Handsaker, R.E., et al.; Global BPgen Consortium; CARDIo-
GRAM Consortium; PR GWAS Consortium; QRS GWAS
Consortium; QT-IGC Consortium; CHARGE-AF Consortium
(2013). Identification of heart rate-associated loci and their
effects on cardiac conduction and rhythm disorders. Nat.
Genet. 45, 621–631.The American121. Chakravarti, A., Clark, A.G., and Mootha, V.K. (2013).
Distilling pathophysiology from complex disease genetics.
Cell 155, 21–26.
122. Teslovich, T.M., Musunuru, K., Smith, A.V., Edmondson,
A.C., Stylianou, I.M., Koseki, M., Pirruccello, J.P., Ripatti, S.,
Chasman, D.I., Willer, C.J., et al. (2010). Biological, clinical
and population relevance of 95 loci for blood lipids. Nature
466, 707–713.
123. Sanseau, P., Agarwal, P., Barnes, M.R., Pastinen, T., Richards,
J.B., Cardon, L.R., and Mooser, V. (2012). Use of genome-
wide association studies for drug repositioning. Nat.
Biotechnol. 30, 317–320.Journal of Human Genetics 93, 779–797, November 7, 2013 797
